Marker Therapeutics, Inc. reports developments as a clinical-stage immuno-oncology company developing non-genetically modified Multi-Antigen Recognizing T cell therapies for hematologic malignancies and solid tumor indications. Its recurring company updates center on the MAR-T cell platform, MT-601 in lymphoma, MT-401-OTS as an off-the-shelf program, and pancreatic cancer research connected to technology developed at Baylor College of Medicine.
Company news also covers clinical observations from named studies, non-dilutive funding from government and cancer-research programs, scientific publications and medical-meeting presentations, quarterly financial results, conference participation, shareholder voting matters, and board governance changes.
Marker Therapeutics, Inc. (Nasdaq: MRKR) announced that the USAN Council has approved "zelenoleucel" as the generic name for MT-401, a T cell therapy targeting acute myeloid leukemia (AML) after stem cell transplants. The therapy, which received Orphan Drug designation in April, has shown clinical benefits in trials. CEO Peter L. Hoang highlighted the significance of this approval as it marks progress in their clinical development and anticipates starting a Phase 2 study for AML patients.